Literature DB >> 17702029

Muscle Nogo-A: a marker for amyotrophic lateral sclerosis or for denervation?

Sven Tågerud, Rolf Libelius, Caroline Magnusson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17702029     DOI： 10.1002/ana.21187

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  5 in total

Review 1.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

2.  Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients.

Authors:  Noam Y Harel; Merit E Cudkowicz; Robert H Brown; Stephen M Strittmatter
Journal:  Biomarkers       Date:  2009-09       Impact factor: 2.658

Review 3.  The role of reticulons in neurodegenerative diseases.

Authors:  Valerio Chiurchiù; Mauro Maccarrone; Antonio Orlacchio
Journal:  Neuromolecular Med       Date:  2013-11-12       Impact factor: 3.843

4.  Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.

Authors:  Vincent Meininger; Pierre-François Pradat; Andrea Corse; Safa Al-Sarraj; Benjamin Rix Brooks; James B Caress; Merit Cudkowicz; Stephen J Kolb; Dale Lange; P Nigel Leigh; Thomas Meyer; Stefano Milleri; Karen E Morrison; Richard W Orrell; Gary Peters; Jeffrey D Rothstein; Jeremy Shefner; Arseniy Lavrov; Nicola Williams; Phil Overend; Jeffrey Price; Stewart Bates; Jonathan Bullman; David Krull; Alienor Berges; Bams Abila; Guy Meno-Tetang; Jens Wurthner
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

Review 5.  Nogo-A and Nogo-66 receptor in amyotrophic lateral sclerosis.

Authors:  Felicia Yu Hsuan Teng; Bor Luen Tang
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.